Navigation Links
Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
Date:8/19/2007

Dr. David S. Smith to Head Regulatory and Quality Affairs

DUBLIN, Calif., Aug. 17 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that Audrey F. Jakubowski, Ph.D., Chief Regulatory and Quality Officer will retire effective today. Dr. Jakubowski's primary responsibilities have been transitioned to David S. Smith, Ph.D., who earlier this year joined SuperGen as Vice President, Regulatory and Quality Affairs.

"Dr. Jakubowski has been extremely instrumental in guiding and growing SuperGen's regulatory and quality efforts over the years," said Dr. James Manuso, President and CEO. "A valued colleague, Audrey created and nurtured a highly effective organization and approach to regulatory affairs and quality management that the Company will continue under Dr. David Smith's leadership."

Dr. Smith, 52, joined SuperGen in March 2007. Prior to joining SuperGen, Dr. Smith was Senior Director, Regulatory Strategy at Wyeth Consumer Healthcare. His responsibilities included obtaining new product registrations on a global level, US marketed product support, and providing scientific and regulatory guidance to business development initiatives. From 1996 to 2000, Dr. Smith served as Regulatory Affairs Program Director at Roche Pharma. Dr. Smith began his regulatory career in 1987 at Schering-Plough, where he focused on the development and registration of oncology and biotechnology products. During his tenure at Schering-Plough, he concentrated on European Union activities and major markets outside of the U.S. Dr. Smith's training includes a post-doctoral fellowship and research in biochemical genetics at the Roche Institute of Molecular Biology. He received a Ph.D. in pharmacology from Wayne State University School of Medicine, and a B.S. in Biophysics, also from Wayne State University.

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Contacts:

Timothy L. Enns Mary M. Vegh

SuperGen, Inc. SuperGen, Inc.

SVP, Corporate Communications Manager, Investor Relations

& Business Development Tel: (925) 560-2845

Tel: (925) 560-0100

E-mail: tenns@supergen.com E-mail: mary.vegh@supergen.com


'/>"/>
SOURCE SuperGen Inc.

Copyright©2007 PR Newswire.

Related biology technology :

1. State technology chief endorses IT audit recommendations
2. Fusion 2007: CA chief says IT complexity raises risk
3. Web-Based Learning Developed under new Chief Education Officer
4. BD IMag Human Regulatory T Lymphocyte Separation Set for Isolation of Treg Cells
5. Emergence of Internet video is changing the regulatory landscape
6. To attract investment, convince manufacturers that regulatory reform is real
7. Support Regulatory Change to Boost Wisconsins Biotech Sector
8. A Simple and Rapid Technique to Purify High-Quality Midiprep DNA
9. Generate High-Quality, Directional Plasmid cDNA Libraries
10. Quality control of antibodies using the 2100 bioanalyzer and the Protein 200 Plus assay
11. Using the Agilent 2100 bioanalyzer for quality control of protein samples prior to MS-analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... regenerative medicine, has announced a new agreement with Bankok,Thailand-based Global Stem Cells Network ... and phsyicians in 15 Latin American countries, including Mexico, Costa Rica, Dominican Republic, ...
(Date:2/10/2016)... Feb. 10, 2016 NX Prenatal Inc., a ... NeXosome® technology for early warning of adverse pregnancy ... recent study by Dr. Thomas McElrath ... Maternal Fetal Medicine,s (SMFM) annual meeting held in ... , 2016.  The presentation reported initial positive top-line ...
(Date:2/10/2016)... BOSTON , Feb. 10, 2016  Matchbook, ... sourcing for fast growing biotech companies, announced today ... Senior Procurement Strategic Advisor. Jim brings nearly 25 ... sourcing and procurement, having spent nearly two decades ... Supply Chain/Logistics and Procurement at Genzyme and, most ...
(Date:2/10/2016)... Mateo, CA (PRWEB) , ... February 10, 2016 ... ... of Multiplex Testing (PROMPT), a research registry built on the secure online PatientCrossroads ... September 2014. More than 1,600 participants have joined the PROMPT study, which seeks ...
Breaking Biology Technology:
(Date:2/3/2016)... 3, 2016 ... the "Emotion Detection and Recognition Market ... Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020" ... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the addition ...
(Date:2/2/2016)... 2, 2016 This BCC Research report ... by reviewing the recent advances in high throughput ... the field forward. Includes forecast through 2019. ... challenges and opportunities that exist in the bioinformatic ... developers, as well as IT and bioinformatics service ...
(Date:2/2/2016)... Feb. 2, 2016 Technology Enhancements Accelerate Growth of ... of the digital and computed radiography markets in ... and Indonesia (TIM). It provides ... size, as well as regional market drivers and restraints. ... market penetration and market attractiveness, both for digital and ...
Breaking Biology News(10 mins):